Peripheral T-Cell Lymphoma, Not Otherwise Specified
Associated Genetic Biomarkers
NCI Definition: A heterogenous category of nodal and extranodal mature T-cell lymphomas that do not correspond to any of the specifically defined entities of mature T-cell lymphoma in the 2017 WHO classification. Excluded from this category are tumors with a T follicular helper (TFH) cell phenotype. Variants include lymphoepithelioid lymphoma (Lennert lymphoma) and primary EBV-positive nodal T-cell or NK-cell lymphoma. The follicular variant included in the peripheral T-cell lymphomas, not otherwise specified, in the 2008 edition of the WHO classification has been moved to the category of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin in the 2017 WHO update. The same is true for a proportion of cases previously designated as the T-zone variant, because they usually have a TFH-cell phenotype. (WHO 2017) 
There are 21 clinical trials for peripheral T-cell lymphoma, not otherwise specified, of which 20 are open and 1 is completed or closed. Of the trials that contain peripheral T-cell lymphoma, not otherwise specified as an inclusion criterion, 1 is early phase 1 (1 open), 7 are phase 1 (7 open), 4 are phase 1/phase 2 (4 open), and 9 are phase 2 (8 open).
ALK is the most frequent gene inclusion criterion for peripheral T-cell lymphoma, not otherwise specified clinical trials .
Cyclophosphamide, brentuximab vedotin, and fludarabine are the most common interventions in peripheral T-cell lymphoma, not otherwise specified clinical trials.
Significant Genes in Peripheral T-Cell Lymphoma, Not Otherwise Specified
ALK is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain ALK status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1/phase 2 (2 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.